Lundbeckfonden Emerge
Lundbeckfonden Emerge seeks to identify and initiate commercial development of scientific opportunities which it considers from its analysis have high commercial potential. The main objective is to turn scientific discoveries and early stage opportunities into commercial ventures with a maturity that allows for full venture financing. Lundbeckfonden Emerge not only offers limited financing for selected cases but also offers seasoned advice or direct participation in new ventures, as part of its unique model to optimize the outcome of the venture to the benefit of all stakeholders. Lundbeckfonden Emerge will seek to develop select projects together with founders and will take on an active role from mentoring to active project management, as is considered optimal for the outcome of the specific project. In this way, Lundbeckfonden Emerge is not a replication of traditional seed funds, but rather a unique way of using research funds to get to commercially viable projects.
NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.
NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.
CytoKi Pharma ApS is a discovery-stage biotechnology company based in Værløse, Denmark, founded in 2019. The company focuses on developing innovative treatments for diseases with significant unmet medical needs, particularly those resulting from epithelial injury. CytoKi Pharma is currently in the pre-clinical stage and is advancing its lead program, which involves an engineered long-acting IL-22 protein licensed from a major pharmaceutical entity. IL-22 is a crucial cytokine that plays a vital role in the immune system's response to tissue injury, acting as a signal for survival and recovery. By harnessing the therapeutic potential of this modified IL-22 protein, CytoKi Pharma aims to address the challenges posed by organ injuries and improve patient outcomes in affected populations.
IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its proprietary T-win technology platform, the company creates immune-modulating cancer vaccines that activate T cells specifically targeting immune-suppressive molecules. This approach aims to induce the immune system to disrupt multiple pathways responsible for tumor-induced immunosuppression. IO Biotech has a solid track record in advancing both preclinical and clinical compounds, with its two lead candidates targeting IDO and PD-L1 currently in clinical development, while several additional therapies remain in the preclinical stage.
AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.
NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.
Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, focusing on the development of CRISPR technology for the treatment of microbial diseases. Established in 2017, the company aims to revolutionize how such diseases are addressed by leveraging the adaptive immune system to create medicines that selectively target and eliminate harmful bacteria based on their specific DNA sequences. By utilizing a novel approach that subverts elements of the endogenous bacterial CRISPR machinery, Snipr Biome provides health professionals with innovative tools for targeted microbiome engineering, enhancing the precision and effectiveness of treatments for bacterial infections.
AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.
NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.